Quick Glance | November's Hot IPOs: Six new stocks, including Hongxinyu and Denglin Technology, are seeing strong subscription demand; Guoxing Aerospace and Xiantong Medicine have passed the listing hearings.

Hello, fellow investors! The NiuNiu IPO Expert is sharing the hot HK IPOs for November and 2026. Come check them out!

As of October 30, $HEMAY PHARMA-B (00054.HK)$ 、 $RELYEZ ENERGY (09621.HK)$ 、 $XINDE SEMI (07672.HK)$ 、 $DENGLIN TECH-P (09917.HK)$ 、 $NEAUTUS (02206.HK)$ 、 $HOSIN ELEC (02681.HK)$ are currently open for strong subscription. In addition, $Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (810760.HK)$ 、 $Adaspace Technology Co., Ltd. (810697.HK)$ Passed the HKEX listing hearing on October 28 and October 29, respectively.

Hemei Pharma-B and Yuanxin Energy Storage ended their IPO subscription at 10:00 on November 4, conducted grey market trading from 16:15 to 18:30 on November 6, and officially listed on November 9. Xinde Semiconductor and Denglin Technology-P ended their IPO subscription at 10:00 on November 5, conducted grey market trading from 16:15 to 18:30 on November 9, and officially listed on November 10. New Hehua ended its IPO subscription at 10:00 on November 6, conducted grey market trading from 16:15 to 18:30 on November 10, and officially listed on November 11. Hongxinyu ended its IPO subscription at 10:00 on November 9, conducted grey market trading from 16:15 to 18:30 on November 11, and officially listed on November 12.

Hemei Pharma-B: Hemei Pharma is a biopharmaceutical company dedicated to the discovery and development of self-discovered and self-developed small-molecule drugs for autoimmune diseases and tumors. It has established expertise in developing treatments and chemotherapies for Psoriasis (Ps), Bipolar Disorder (BD), and Inflammatory Bowel Disease (IBD). As of the latest practicable date, the company has developed a product pipeline that includes Mufemilast, a drug approved by the National Medical Products Administration (NMPA), as well as five other small-molecule candidate drugs, covering various indications with unmet medical needs.

Yuanxin Energy Storage: Yuanxin Energy Storage is a provider of integrated energy storage system solutions in China, focusing on offering comprehensive energy storage system solutions, hardware products, software system platforms, and supporting services. Its offerings cover all key stages of energy storage projects, from asset development and delivery to operation and management. The company engages in the R&D, manufacturing, and sales of energy storage system solutions and products, and provides supporting services to customers in China and overseas.

Xinde Semiconductor: Xinde Semiconductor is a semiconductor packaging and testing service provider, primarily engaged in developing packaging designs, providing customized packaging products, and offering packaging product testing services. According to Frost & Sullivan, in the "post-Moore era," where transistor density growth is approaching its physical limits, relying on new semiconductor packaging architectures as a key link connecting chip design and applications has become a critical driver for enhancing chip performance, efficiency, and functional flexibility.

Denglin Technology-P: Denglin Technology is a provider of General-Purpose Graphics Processing Units (GPGPUs), developing and selling GPGPU products to meet the AI computing needs across various industries in China. Leveraging its independently developed, software-defined on-chip heterogeneous proprietary computing framework, the GPU+ (Minsky™) architecture, the company targets enterprise AI as its core market and seeks to expand into innovative fields such as public cloud markets and robotics. By providing high-energy-efficiency, secure, and reliable computing power platforms and scenario-based solutions, the company aims to become a solid partner in China's industrial AI upgrade process.

New Hehua: New Hehua is a major supplier of Traditional Chinese Medicine (TCM) decoction pieces in China. Based on revenue from TCM decoction pieces in 2025, the company ranks 2nd in China, holding a 0.4% market share in a highly competitive landscape, while the top five market participants collectively hold a 2.7% market share. The company formulates and implements rigorous standards for TCM production and quality control, integrating digital technologies into its production and quality control processes.

Hongxinyu: Hongxinyu is a memory manufacturer. According to Frost & Sullivan, in 2025, the company held a 0.6% market share by revenue in the global memory product market and ranked 12th among all global memory manufacturers. Leveraging its existing customer network, the company will continue to expand the application scenarios of its memory products in the AI era and connect with more customers.

Which upcoming IPO are fellow investors most looking forward to? Will other companies you care about successfully list on the HKEX in the future? Come vote and interact in the comments section!

– "Memory manufacturer" Hongxinyu launches IPO subscription, planning to list on November 12, with a minimum lot subscription amount of HK$8,373.6.

– General-purpose GPU provider Dengleng Technology has launched its IPO, with plans to list on November 10. The minimum subscription amount for one lot is HKD 7,272.61.

– Biopharmaceutical company Hemei Pharmaceutical-B has launched its IPO, with plans to list on November 9. The minimum subscription amount for one lot is HKD 1,909.06.

– HKEX releases "T+1" implementation roadmap: Timeline postponed to 2028 as market needs time for full preparation

The golden season for IPO subscriptions is here! Subscribe to IPOs with Futu: 0% interest, 0 fees, and cash-free subscription. Participate in the campaign now for a chance to waive IPO subscription fees for one year.Try it out now >>

Edited by Vincent

60K Views